Endometriosis
Conditions
Keywords
Chronic pelvic pain, Transcutaneous Auricular Vagus Nerve Stimulation
Brief summary
6-10% of women of childbearing age suffer from endometriosis, which is mainly manifested by dysmenorrhea, non-menstrual pelvic pain and dyspareunia. Several treatment strategies, including surgical ones, are proposed but they are sometimes insufficient because endometriosis-related pain is frequently accompanied by sensitization. Endometriosis surgery, when indicated, is therefore changeably effective, even though the lesions have been completely resected. Patients therefore consult Pain Units seeking for the effective treatment as the pain persist even after surgical management of endometriosis. Vagus nerve stimulation is a non-invasive technique that includes an anti-inflammatory effect and a modulation of neurotransmitter production (adrenaline, norepinephrine; serotonin, acetylcholine). Yuan and Silberstein published a general review on the technique. Migraine and depression are one of the selected indications. In addition, Napadow et al. published favourable results in a short series of patients with chronic pelvic pain. The Investigators of this study have treated some patients with this technique with a result deemed satisfactory which leads to propose a randomized study to confirm this impression.
Interventions
DEVICETranscutaneous Auricular Vagus Nerve Stimulation
Transcutaneous Auricular Vagus Nerve Stimulation has an eartip connected to an external stimulator. The device used in this study is the TENS Eco Plus commercialized by Schwa Medico and European Compliance (CE) marked. The electrode is positioned in the cymba concha of the left ear.
Sponsors
Hopital Foch
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
15 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Women aged \>= 15 years * With chronic pelvic pain and/ or dysmenorrhoea and/ or dyspareunia * Who has been cared for by a gynecologist in one of the institutions participating in the study * Diagnosed with endometriosis * Having signed an informed written consent * Affiliated to a health insurance scheme
Exclusion criteria
* contraindication to the use of transcutaneous auricular vagus nerve stimulation (cardiac pathology, asthmatic patient) * pregnant or breastfeeding women * patient undergoing in vitro fertilization * associated pathology requiring long-term analgesic treatment * patient with atria trans vagal neurostimulation in the 12 months prior to inclusion * patient deprived of liberty or under guardianship
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change of symptoms related to the pelvic pain | 3 months after enrolment | Self assessement of change using Patient's Global Impression of Change (PGIC) scale in which patients rate the improvement of their symptoms related to their pelvic pain from No change or it get worse to A great deal better, and a considerable improvement that has made all the difference . A favorable result will be Better, and a definite improvement that has made a real and worthwhile difference or A great deal better, and a considerable improvement that has made all the difference |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy on severity of patient's symptoms | Day 1 and 3 months after enrolment | Physician assessement of severity of patient's symptoms using Global Clinical Impressions-Severity scale on which physicians rate the severity of patient's symptoms from not evaluated to Among the sickest patients |
| Efficacy on quality of life | Day 1 and 3 months after enrolment | Self assessement of quality of life using Endometriosis Health Profile-5 |
| Efficacy on Anxiety | Day 1 and 3 months after enrolment | Self assessement of anxiety using the Hospital Anxiety and Depression scale |
| Efficacy on pain | Day 1 and 3 months after enrolment | Self assessement of pain using Endometriosis-associated pelvic pain scale on which patients rate their current pain intensity from 0 No pain to 10 worst possible pain |
| General efficacy of the device Transcutaneous Electronic Neuro Stimulation TENS Eco Plus | 3 months after enrolment | Self assessement of satisfaction using a satisfaction questionnaire involving satisfaction, adherence to treatment sessions and ease of use of the device |
| Collection of possible side effects | 3 months after Enrolement | collection of vagal malaise, nausea and vomiting |
| Efficacy on gynecological and pelvic pain symptoms | Day 1 and 3 months after enrolment | Self assessement of gynecological and pelvic pain symptoms using ENDOL-4D questionnaire |
Countries
France
Contacts
Primary ContactMireille MICHEL-CHERQUI, MD
Outcome results
None listed